US 12,290,517 B2
Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
Joseph Paul Bullock, Fort Worth, TX (US); Chinmay Maheshwari, Mason, OH (US); Quintus Medley, Wellesley, MA (US); Muneto Mogi, Waltham, MA (US); Michela Montecchi-Palmer, Fort Worth, TX (US); and Kalliopi Stasi, Watertown, MA (US)
Assigned to Bausch + Lomb Ireland Limited, Dublin (IE)
Filed by Bausch + Lomb Ireland Limited, Dublin (IE)
Filed on Sep. 8, 2022, as Appl. No. 17/930,578.
Application 17/930,578 is a division of application No. 16/789,976, filed on Feb. 13, 2020, granted, now 11,478,480.
Claims priority of provisional application 62/806,705, filed on Feb. 15, 2019.
Prior Publication US 2023/0139170 A1, May 4, 2023
Int. Cl. A61K 47/02 (2006.01); A61K 9/48 (2006.01); A61K 31/517 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 9/0048 (2013.01)] 15 Claims
 
1. A method of treating ocular surface pain in a subject in need thereof, comprising ocularly administering to the subject a formulation, comprising:
a suspension of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)benzonitrile (compound I) or a salt, co-crystal, or polymorph thereof, in an amount of about 0.5% w/v to about 3.5% w/v;
tyloxapol in an amount of about 0.04% w/v to about 0.06% w/V;
carbomer homopolymer Type B in an amount from about 0.05% w/v to about 0.4% w/v;
a tonicity agent;
a buffer;
sodium chloride in an amount of from 0.01% w/v to about 1% w/V;
optionally, a preservative; and
water in quantity sufficient (qs) to 100%.